• +1-646-491-9876
    • +91-20-67278686

    Search

    Autism-Pipeline Review H2 2017

    Autism-Pipeline Review H2 2017

    • Report Code ID: RW0001881447
    • Category Life Sciences
    • No. of Pages 138
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Autism-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review H2 2017 provides an overview of the Autism (Central Nervous System) pipeline landscape.

    Autism also known as complex developmental disability is a neurodevelopment disorder characterized by social interaction verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex family history fragile X syndrome Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors) antidepressants antipsychotics and sedatives. 

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Autism-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Autism (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I IND/CTA Filed Preclinical Discovery and Unknown stages are 1 2 6 4 1 18 3 and 2 respectively. Similarly the Universities portfolio in Phase II Phase I Preclinical and Discovery stages comprises 1 1 1 and 1 molecules respectively.

    Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Autism-Overview
    Autism-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Autism-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Autism-Companies Involved in Therapeutics Development
    4D Pharma PLC
    Addex Therapeutics Ltd
    Aequus Pharmaceuticals Inc
    Aevi Genomic Medicine Inc
    AgeneBio Inc
    Anima Biotech Ltd
    APeT Holding BV
    BioCrea GmbH
    BioHealthonomics Inc
    BrainStorm Cell Therapeutics Inc
    Confluence Pharmaceuticals LLC
    Coronis NeuroSciences Ltd
    Curemark LLC
    DRI Biosciences Corp
    F. Hoffmann-La Roche Ltd
    GW Pharmaceuticals Plc
    Heptares Therapeutics Ltd
    Immuron Ltd
    Intra-Cellular Therapies Inc
    Leading BioSciences Inc
    MedDay SA
    Omeros Corp
    OptiNose US Inc
    Ovensa Inc
    Q BioMed Inc
    Sumitomo Dainippon Pharma Co Ltd
    Autism-Drug Profiles
    acamprosate calcium-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ACT-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADX-71441-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADX-88178-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody to Inhibit Lipopolysaccharide for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aripiprazole-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASD-002-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologics for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CB-0306-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CM-AT-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CP-102-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fasoracetam-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GWP-42006-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    histamine dihydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HTL-14242-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMM-124E-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-179-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lumateperone tosylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lurasidone hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MD-1103-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    niacinamide CR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NurOwn-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    oxytocin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PAM-28-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Insulin Like Growth Factor 1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-7314-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SERx-519-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-999-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GABRA5 Receptor for CNS Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Target GPR63 for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Target Oxytocin for Autism and Anxiety Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize CB1 and CB2 for Autism Eczema and Insomnia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for CNS Disorders Rheumatoid Arthritis Osteoarthritis Bronchopulmonary Dysplasia and Heart Failure-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTA-121-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Autism-Dormant Projects
    Autism-Discontinued Products
    Autism-Product Development Milestones
    Featured News & Press Releases
    Apr 19 2017 BrainStorm Announces Publication of NurOwn Autism Research Study
    Feb 23 2017 Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism-The BlUm Study
    Sep 22 2016 Blum Study-A Phase 3 Clinical Trial for Children with Autism
    Jul 20 2016 Immuron to Cooperate with Leading Australian Universities on Autism Research
    Feb 04 2016 Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
    Jul 23 2015 Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
    May 11 2015 Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
    Nov 04 2013 Curemark Begins NDA Submission for CM-AT Autism Treatment
    Apr 23 2013 Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
    Aug 15 2012 Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
    Aug 06 2012 Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
    May 31 2012 Study Reports New Treatment For Irritability In Autism
    Dec 07 2011 Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
    Mar 21 2011 Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
    Oct 27 2010 Curemark Adds Two Autism Trial Sites In California
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Autism H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Autism-Pipeline by 4D Pharma PLC H2 2017
    Autism-Pipeline by Addex Therapeutics Ltd H2 2017
    Autism-Pipeline by Aequus Pharmaceuticals Inc H2 2017
    Autism-Pipeline by Aevi Genomic Medicine Inc H2 2017
    Autism-Pipeline by AgeneBio Inc H2 2017
    Autism-Pipeline by Anima Biotech Ltd H2 2017
    Autism-Pipeline by APeT Holding BV H2 2017
    Autism-Pipeline by BioCrea GmbH H2 2017
    Autism-Pipeline by BioHealthonomics Inc H2 2017
    Autism-Pipeline by BrainStorm Cell Therapeutics Inc H2 2017
    Autism-Pipeline by Confluence Pharmaceuticals LLC H2 2017
    Autism-Pipeline by Coronis NeuroSciences Ltd H2 2017
    Autism-Pipeline by Curemark LLC H2 2017
    Autism-Pipeline by DRI Biosciences Corp H2 2017
    Autism-Pipeline by F. Hoffmann-La Roche Ltd H2 2017
    Autism-Pipeline by GW Pharmaceuticals Plc H2 2017
    Autism-Pipeline by Heptares Therapeutics Ltd H2 2017
    Autism-Pipeline by Immuron Ltd H2 2017
    Autism-Pipeline by Intra-Cellular Therapies Inc H2 2017
    Autism-Pipeline by Leading BioSciences Inc H2 2017
    Autism-Pipeline by MedDay SA H2 2017
    Autism-Pipeline by Omeros Corp H2 2017
    Autism-Pipeline by OptiNose US Inc H2 2017
    Autism-Pipeline by Ovensa Inc H2 2017
    Autism-Pipeline by Q BioMed Inc H2 2017
    Autism-Pipeline by Sumitomo Dainippon Pharma Co Ltd H2 2017
    Autism-Dormant Projects H2 2017
    Autism-Dormant Projects H2 2017 (Contd..1) H2 2017
    Autism-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Autism H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    4D Pharma PLC
    Addex Therapeutics Ltd
    Aequus Pharmaceuticals Inc
    Aevi Genomic Medicine Inc
    AgeneBio Inc
    Anima Biotech Ltd
    APeT Holding BV
    BioCrea GmbH
    BioHealthonomics Inc
    BrainStorm Cell Therapeutics Inc
    Confluence Pharmaceuticals LLC
    Coronis NeuroSciences Ltd
    Curemark LLC
    DRI Biosciences Corp
    F. Hoffmann-La Roche Ltd
    GW Pharmaceuticals Plc
    Heptares Therapeutics Ltd
    Immuron Ltd
    Intra-Cellular Therapies Inc
    Leading BioSciences Inc
    MedDay SA
    Omeros Corp
    OptiNose US Inc
    Ovensa Inc
    Q BioMed Inc
    Sumitomo Dainippon Pharma Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//autism-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//autism-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//autism-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments